Company news
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news
Ionis Pharmaceuticals, Inc. news releases on 6ix. Latest, Nov 7, 2021: Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema…
Press releases — page 5
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
November 6, 2021
Ionis reports third quarter 2021 financial results and recent business achievements
November 2, 2021
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
November 1, 2021
Ionis to hold third quarter 2021 financial results webcast
October 19, 2021
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
October 16, 2021
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
September 2, 2021
Ionis reports second quarter 2021 financial results and recent business achievements
August 3, 2021
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
July 28, 2021
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
July 12, 2021
Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
June 13, 2021
Ionis announces changes to its board of directors at annual meeting of stockholders
June 1, 2021
Ionis reports first quarter 2021 financial results and recent business achievements
May 4, 2021
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
April 19, 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
April 4, 2021
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
March 28, 2021
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
February 28, 2021
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
February 23, 2021
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
January 6, 2021
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
December 16, 2020
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
November 30, 2020
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
November 22, 2020
Ionis reports third quarter 2020 financial results and recent business achievements
November 3, 2020
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
November 2, 2020
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
October 21, 2020
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
October 11, 2020
Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
September 30, 2020
Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
September 29, 2020
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
September 17, 2020
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
August 30, 2020
Ionis reports second quarter 2020 financial results and recent business achievements
August 4, 2020
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
July 21, 2020
Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
June 28, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
June 7, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
May 31, 2020
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
May 27, 2020
Akcea Announces Appointment of New Chief Financial Officer
May 17, 2020
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
May 13, 2020
Ionis reports first quarter 2020 financial results and recent business achievements
May 5, 2020
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
April 19, 2020
Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs
April 7, 2020
Ionis provides fourth quarter and full year 2019 financial results
February 25, 2020
Ionis Pharmaceuticals to hold 2019 financial results webcast
February 18, 2020
Ionis treatment for Alexander disease granted orphan drug status from EMA
February 10, 2020
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
January 9, 2020
Ionis' neurological franchise marks year of achievement
January 6, 2020
Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024
December 11, 2019
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
November 24, 2019
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
November 18, 2019
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
October 21, 2019
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
October 8, 2019